Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Saved in:
| Title: | Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. |
|---|---|
| Authors: | Catenacci DV, Kang YK, Uronis HE, Lee KW, Ng MC, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Oh DY, Yen J, Odegaard JI, Lagow E, Li D, Sun J, Kaminker P, Moore PA, Rosales MK, Park H |
| Source: | Oncology (Williston Park, N.Y.) [Oncology (Williston Park)] 2023 Apr 25; Vol. 37 (4), pp. 176-183. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: MultiMedia Healthcare Country of Publication: United States NLM ID: 8712059 Publication Model: Print Cited Medium: Internet ISSN: 0890-9091 (Print) Linking ISSN: 08909091 NLM ISO Abbreviation: Oncology (Williston Park) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
